Portal de Periódicos da CAPES

Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register

2020; SAGE Publishing; Volume: 26; Linguagem: Inglês

10.1177/1076029620945792

1938-2723

Emilia Antonucci, Ludovica Migliaccio, Maria Abbattista, Antonella Caronna, Sergio De Marchi, Angela Di Giorgio, Rosella Di Giulio, Teresa Lerede, Mariagrazia Garzia, Ida Martinelli, Daniela Mastroiacovo, Marco Marzolo, Elisa Montevecchi, Daniele Pastori, Pasquale Pignatelli, Daniela Poli, Luigi Ria, Angelo Santoliquido, Sophie Testa, Gualtiero Palareti,

Diagnosis and Treatment of Venous Diseases

Patients with venous thromboembolism (VTE) should receive a decision on the duration of anticoagulant treatment (AT) that is often not easy to make. Sixteen Italian clinical centers included patients with recent VTE in the START2-POST-VTE register and reported the decisions taken on duration of AT in each patient and the reasons for them. At the moment of this report, 472 (66.9%) of the 705 patients included in the registry were told to stop AT in 59.3% and to extend it in 40.7% of patients. Anticoagulant treatment lasted ≥3 months in >90% of patients and was extended in patients with proximal deep vein thrombosis because considered at high risk of recurrence or had thrombophilic abnormalities. d-dimer testing, assessment of residual thrombus, and patient preference were also indicated among the criteria influencing the decision. In conclusion, Italian doctors stuck to the minimum 3 months AT after VTE, while the secondary or unprovoked nature of the event was not seen as the prevalent factor influencing AT duration which instead was the result of a complex and multifactorial evaluation of each patient.